GSK has selected two Flagship Pioneering portfolio companies — Profound (proteomics) and Quotient (somatic genomics) — as the first collaborators under a multi‑program discovery framework intended to surface targets for respiratory and liver diseases. The feasibility pacts are the first company‑level projects launched under the broader Flagship‑GSK collaboration. Profound will apply its ProFoundry proteomics platform and high‑throughput functional validation to proteins genetically linked to COPD and IPF. Quotient will deploy somatic genomics to identify causal drivers in COPD, IPF and MASH, with GSK holding exclusive options to advance programs into preclinical and clinical development. Under the umbrella deal, Flagship companies may receive up‑front funding and are eligible for substantial development and commercial milestones if GSK exercises its options. The moves underscore Big Pharma’s continuing strategy of buying or partnering with platform firms to accelerate target discovery and de‑risk early R&D.